Vertice Pharma announced the launch of Thyquidity™ (levothyroxine sodium) oral solution.
Thyquidity is indicated for the treatment of hypothyroidism – as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 1 Liter Glass Bottle With Lid
It is also approved for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
The product is supplied in 100mL amber glass bottles containing 100mcg of levothyroxine sodium per 5mL. Thyquidity should be administered directly to the mouth using a calibrated oral syringe.
Latest News Your top articles for Friday
Haymarket Medical Network Top Picks
Continuing Medical Education (CME/CE) Courses
Please login or register first to view this content.